News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Artimplant Interim Report January - June 2010
August 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
VÄSTRA FRÖLUNDA, Sweden--(BUSINESS WIRE)--Artimplant (STO:ARTIB): -- Net revenue for the second quarter amounted to SEK 5.1 million (7.9) and for the first six months SEK 9.8 million (12.8).*
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Layoff Tracker
Ultragenyx Downsizes By 10% After Bone Drug’s Phase 3 Fail
February 13, 2026
·
54 min read
·
BioSpace Editorial Staff
Vaccines
Flu Vaccine Rejection Imperils Moderna’s Breakeven Plans
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
People
Sanofi Shares Decline as Paul Hudson Removed as CEO, Making Way For Merck KGaA’s Belén Garijo
February 12, 2026
·
2 min read
·
Annalee Armstrong
Insights
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
February 12, 2026
·
1 min read
·
Jennifer Smith-Parker
